Acute Kidney Injury and Renal Replacement Therapy in Critically Ill COVID-19 Patients: Risk Factors and Outcomes: A Single-Center Experience in Brazil.

Critically ill patients with COVID-19 may develop multiple organ dysfunction syndrome, including acute kidney injury (AKI). We report the incidence, risk factors, associations, and outcomes of AKI and renal replacement therapy (RRT) in critically ill COVID-19 patients. We performed a retrospective cohort study of adult patients with COVID-19 diagnosis admitted to the intensive care unit (ICU) between March 2020 and May 2020. Multivariable logistic regression analysis was applied to identify risk factors for the development of AKI and use of RRT. The primary outcome was 60-day mortality after ICU admission. 101 (50.2%) patients developed AKI (72% on the first day of invasive mechanical ventilation [IMV]), and thirty-four (17%) required RRT. Risk factors for AKI included higher baseline Cr (OR 2.50 [1.33-4.69], p = 0.005), diuretic use (OR 4.14 [1.27-13.49], p = 0.019), and IMV (OR 7.60 [1.37-42.05], p = 0.020). A higher C-reactive protein level was an additional risk factor for RRT (OR 2.12 [1.16-4.33], p = 0.023). Overall 60-day mortality was 14.4% {23.8% (n = 24) in the AKI group versus 5% (n = 5) in the non-AKI group (HR 2.79 [1.04-7.49], p = 0.040); and 35.3% (n = 12) in the RRT group versus 10.2% (n = 17) in the non-RRT group, respectively (HR 2.21 [1.01-4.85], p = 0.047)}. AKI was common among critically ill COVID-19 patients and occurred early in association with IMV. One in 6 AKI patients received RRT and 1 in 3 patients treated with RRT died in hospital. These findings provide important prognostic information for clinicians caring for these patients.

Doher MP ，Torres de Carvalho FR ，Scherer PF ，Matsui TN ，Ammirati AL ，Caldin da Silva B ，Barbeiro BG ，Carneiro FD ，Corrêa TD ，Ferraz LJR ，Dos Santos BFC ，Pereira VG ，Batista MC ，Monte JCM ，Santos OFP ，Bellomo R ，Serpa Neto A ，Durão MS ... -  《-》

Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study.

Lowe R ，Ferrari M ，Nasim-Mohi M ，Jackson A ，Beecham R ，Veighey K ，Cusack R ，Richardson D ，Grocott M ，Levett D ，Dushianthan A ，University Hospital Southampton Critical Care Team and the REACT COVID investigators ... -  《BMC Nephrology》

Epidemiology and Outcomes of Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome: A Multicenter Retrospective Study.

Acute kidney injury (AKI) is associated with increased mortality in patients with acute respiratory distress syndrome (ARDS). However, the epidemiological features and outcomes of AKI among COVID-19 patients with ARDS are unknown. We retrospectively recruited consecutive adult COVID-19 patients who were diagnosed with ARDS according to Berlin definition from 13 designated intensive care units in the city of Wuhan, China. Potential risk factors of AKI as well as the relation between AKI and in-hospital mortality were investigated. A total of 275 COVID-19 patients with ARDS were included in the study, and 49.5% of them developed AKI during their hospital stay. In comparison with patients without AKI, patients who developed AKI were older, tended to have chronic kidney disease, had higher Sepsis-Related Organ Failure Assessment score on day 1, and were more likely to receive invasive ventilation and develop acute organ dysfunction. Multivariate analysis showed that age, history of chronic kidney disease, neutrophil-to-lymphocyte ratio, and albumin level were independently associated with the occurrence of AKI. Importantly, increasing AKI severity was associated with increased in-hospital mortality when adjusted for other potential variables: odds ratio of stage 1 = 5.374 (95% CI: 2.147-13.452; p < 0.001), stage 2 = 6.216 (95% CI: 2.011-19.210; p = 0.002), and stage 3 = 34.033 (95% CI: 9.723-119.129; p < 0.001). In this multicenter retrospective study, we found that nearly half of COVID-19 patients with ARDS experienced AKI during their hospital stay. The coexistence of AKI significantly increased the mortality of these patients.

Wang F ，Ran L ，Qian C ，Hua J ，Luo Z ，Ding M ，Zhang X ，Guo W ，Gao S ，Gao W ，Li C ，Liu Z ，Li Q ，Ronco C ... -  《-》

Outcomes of renal replacement therapy in the critically ill with COVID-19.

To describe outcomes of critically ill patients with COVID-19, particularly the association of renal replacement therapy to mortality. A single-center prospective observational study was carried out. ICU of a tertiary care center. Consecutive adults with COVID-19 admitted to the ICU. Renal replacement therapy. Demographic data, medical history, illness severity, type of oxygen therapy, laboratory data and use of renal replacement therapy to generate a logistic regression model describing independent risk factors for mortality. Of the total of 166 patients, 51% were mechanically ventilated and 26% required renal replacement therapy. The overall hospital mortality rate was 36%, versus 56% for those requiring renal replacement therapy, and 68% for those with both mechanical ventilation and renal replacement therapy. The logistic regression model identified four independent risk factors for mortality: age (adjusted OR 2.8 [95% CI 1.8-4.4] for every 10-year increase), mechanical ventilation (4.2 [1.7-10.6]), need for continuous venovenous hemofiltration (2.3 [1.3-4.0]) and C-reactive protein (1.1 [1.0-1.2] for every 10mg/L increase). In our cohort, acute kidney injury requiring renal replacement therapy was associated to a high mortality rate similar to that associated to the need for mechanical ventilation, while multiorgan failure necessitating both techniques implied an extremely high mortality risk.

Burke E ，Haber E ，Pike CW ，Sonti R ... -  《-》

COVID-19-associated acute kidney injury patients treated with renal replacement therapy in the intensive care unit: A multicenter study in São Paulo, Brazil.

Samaan F ，Carneiro de Paula E ，de Lima Souza FBG ，Mendes LFC ，Rossi PRG ，Freitas RAP ，Nakagawa FT ，Maciel AT ，Aranha S ，Osawa E ，Konigsfeld HP ，da Silva RG ，de Souza RBC ，Coutinho SM ，Vieira TD ，Thomaz KB ，Flato EMS ，da Silva RC ，Andrade LV ，Badaoui M ，Badaoui EP ，Goes MÂ ，do Amaral SH ，Cunha K ，Muniz IM ，Sampaio JS ，Durão Junior MS ，Zanetta DMT ，Burdmann EA ... -  《PLoS One》